Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Alzamend Neuro, Inc. on April 17, 2026. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Capital Market under the symbol ALZN. As of the record date (February 25, 2026), there were 3,804,741 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent 10-K or 10-Q filings for financial statements.
Material Changes and Stockholder Votes
Stockholders voted on seven proposals at the Annual Meeting. All seven proposals were approved. Key voting outcomes include:
- Proposal 1 (Director Election): Seven directors were elected. While approved, each nominee received significant "Against" votes (ranging from approximately 58,000 to 71,000) and substantial broker non-votes (1,185,412 per nominee).
- Proposal 2 (Auditor Ratification): Ratified Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2026.
- Proposal 3 (Executive Compensation): Approved the compensation of named executive officers on a non-binding advisory basis.
- Proposal 4 (Stock Incentive Plan): Approved the 2025 Stock Incentive Plan.
- Proposal 5 (Equity Issuances): Approved equity issuances to directors and executive officers to comply with Nasdaq Listing Rule 5635(c).
- Proposal 6 (Reverse Stock Split): Approved an amendment to the Certificate of Incorporation to effect a reverse stock split of Common Stock by a ratio of not less than one-for-two and not more than one-for-ten. The exact ratio is to be determined by the Board of Directors at its sole discretion prior to April 16, 2027.
- Proposal 7 (Adjournment): Approved the ability to adjourn the meeting to solicit further proxies if necessary.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the standard disclosures referenced in the Proxy Statement. The approval of the reverse stock split authority (Proposal 6) indicates a strategic intent to potentially adjust the share structure, which is often associated with maintaining listing compliance or improving market perception, though the specific timing and ratio remain undetermined.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and implementation date, as the Board retains discretion to set a ratio between 1-for-2 and 1-for-10 prior to April 16, 2027.
- Review the definitive Proxy Statement (Schedule 14A filed February 26, 2026) for details on the significant "Against" votes cast for director nominees and executive compensation.
- Confirm the impact of the approved 2025 Stock Incentive Plan on future dilution.
- Check subsequent filings for the official announcement of the reverse stock split ratio and effective date.